Bora Pharmaceuticals Co Ltd(TW:6472)
NT$403.00+11.50 (+2.94%)
TW:6472
Bora Pharmaceuticals Co Ltd financials statements
NT$403.00
At close:+11.50 (+2.94%)
Bora Pharmaceuticals Co Ltd (6472) Ratios
Bora Pharmaceuticals Co Ltd Ratios
TW:6472's free cash flow for Q2 2026 was NT$349.39M. For the 2026 fiscal year, TW:6472's free cash flow was decreased by NT$-341.18M and operating cash flow was NT$690.58M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.45 | 1.71 | 1.29 | 1.17 | 1.52 |
| Quick Ratio | 1.20 | 1.31 | 1.03 | 0.98 | 1.02 |
| Cash Ratio | 0.38 | 0.42 | 0.37 | 0.31 | 0.49 |
| Solvency Ratio | 0.14 | 0.16 | 0.27 | 0.10 | 0.23 |
| Operating Cash Flow Ratio | 0.32 | 0.07 | 0.56 | 0.19 | 0.67 |
| Short-Term Operating Cash Flow Coverage | 0.75 | 0.26 | 3.26 | 0.70 | 1.43 |
| Net Current Asset Value | NT$ -7.90B | NT$ -7.02B | NT$ -2.68B | NT$ -5.38B | NT$ -1.43B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.41 | 0.42 | 0.20 | 0.33 | 0.30 |
| Debt-to-Equity Ratio | 1.19 | 1.47 | 0.55 | 1.68 | 0.71 |
| Debt-to-Capital Ratio | 0.54 | 0.60 | 0.36 | 0.63 | 0.41 |
| Long-Term Debt-to-Capital Ratio | 0.43 | 0.53 | 0.23 | 0.47 | 0.25 |
| Financial Leverage Ratio | 2.91 | 3.54 | 2.76 | 5.03 | 2.34 |
| Debt Service Coverage Ratio | 0.56 | 1.30 | 3.06 | 0.61 | 1.10 |
| Interest Coverage Ratio | 6.80 | 7.05 | 30.65 | 17.92 | 20.10 |
| Debt to Market Cap | 0.29 | 0.24 | 0.06 | 0.11 | 0.04 |
| Interest Debt Per Share | 150.00 | 158.75 | 43.06 | 65.86 | 24.43 |
| Net Debt to EBITDA | 3.10 | 2.04 | 0.33 | 1.90 | 1.02 |
| Profitability Margins | |||||
| Gross Profit Margin | 40.29% | 40.06% | 49.23% | 27.76% | 34.12% |
| EBIT Margin | 17.32% | 28.24% | 36.97% | 18.32% | 21.35% |
| EBITDA Margin | 22.25% | 33.57% | 41.24% | 21.67% | 26.28% |
| Operating Profit Margin | 17.32% | 17.58% | 36.97% | 18.57% | 21.99% |
| Pretax Profit Margin | 27.76% | 25.75% | 28.62% | 17.53% | 20.90% |
| Net Profit Margin | 15.68% | 20.47% | 21.34% | 13.26% | 15.30% |
| Continuous Operations Profit Margin | 23.40% | 20.99% | 21.63% | 13.35% | 15.30% |
| Net Income Per EBT | 56.49% | 79.50% | 74.56% | 75.65% | 73.22% |
| EBT Per EBIT | 160.25% | 146.48% | 77.43% | 94.42% | 95.02% |
| Return on Assets (ROA) | 6.67% | 8.64% | 12.10% | 6.12% | 10.17% |
| Return on Equity (ROE) | 19.38% | 30.61% | 33.35% | 30.74% | 23.78% |
| Return on Capital Employed (ROCE) | 10.49% | 10.64% | 31.20% | 15.89% | 19.48% |
| Return on Invested Capital (ROIC) | 7.48% | 7.73% | 21.63% | 9.75% | 12.30% |
| Return on Tangible Assets | 7.75% | 10.32% | 15.57% | 6.75% | 10.41% |
| Earnings Yield | 4.90% | 5.12% | 4.66% | 2.30% | 1.55% |
| Efficiency Ratios | |||||
| Receivables Turnover | 1.98 | 1.68 | 3.53 | 1.64 | 5.71 |
| Payables Turnover | 12.29 | 14.67 | 19.94 | 16.78 | 14.17 |
| Inventory Turnover | 3.33 | 2.10 | 3.34 | 3.89 | 3.53 |
| Fixed Asset Turnover | 1.70 | 1.54 | 1.89 | 1.43 | 1.20 |
| Asset Turnover | 0.43 | 0.42 | 0.57 | 0.46 | 0.66 |
| Working Capital Turnover Ratio | 2.41 | 3.17 | 6.89 | 7.78 | 7.59 |
| Cash Conversion Cycle | 264.35 | 366.11 | 194.41 | 294.79 | 141.45 |
| Days of Sales Outstanding | 184.39 | 216.89 | 103.54 | 222.82 | 63.91 |
| Days of Inventory Outstanding | 109.65 | 174.10 | 109.17 | 93.72 | 103.30 |
| Days of Payables Outstanding | 29.69 | 24.89 | 18.31 | 21.75 | 25.77 |
| Operating Cycle | 294.04 | 390.99 | 212.71 | 316.54 | 167.22 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 34.00 | 8.00 | 38.35 | 17.18 | 13.25 |
| Free Cash Flow Per Share | 26.56 | 2.40 | 26.46 | 15.47 | 9.35 |
| Dividend Paid and CapEx Coverage Ratio | 1.78 | 0.51 | 2.25 | 4.58 | 2.61 |
| Capital Expenditure Coverage Ratio | 4.57 | 1.43 | 3.23 | 10.04 | 3.40 |
| Operating Cash Flow Coverage Ratio | 0.23 | 0.05 | 0.92 | 0.26 | 0.56 |
| Operating Cash Flow to Sales Ratio | 0.22 | 0.05 | 0.32 | 0.19 | 0.25 |
| Free Cash Flow Yield | 5.44% | 0.38% | 4.90% | 2.99% | 1.81% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 20.42 | 19.51 | 21.46 | 43.48 | 80.21 |
| Price-to-Sales (P/S) Ratio | 3.20 | 3.99 | 4.58 | 5.77 | 9.85 |
| Price-to-Book (P/B) Ratio | 3.96 | 5.97 | 7.16 | 13.36 | 15.31 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 18.37 | 261.71 | 20.42 | 33.43 | 55.29 |
| Price-to-Operating Cash Flow Ratio | 14.35 | 78.38 | 14.09 | 30.10 | 39.03 |
| Price-to-Earnings Growth (PEG) Ratio | -0.80 | 0.71 | 0.19 | 0.51 | 2.87 |
| Enterprise Value Multiple | 17.49 | 13.93 | 11.44 | 28.51 | 38.51 |
| Enterprise Value | 73.99B | 90.03B | 66.98B | 64.83B | 49.59B |
| EV to EBITDA | 17.49 | 13.93 | 11.44 | 28.51 | 38.51 |
| EV to Sales | 3.89 | 4.68 | 4.72 | 6.18 | 10.12 |
| EV to Free Cash Flow | 22.33 | 306.47 | 21.04 | 35.82 | 56.79 |
| EV to Operating Cash Flow | 17.44 | 91.79 | 14.52 | 32.25 | 40.10 |
| Tangible Book Value Per Share | 90.00 | 61.74 | 51.29 | 25.58 | 31.94 |
| Shareholders’ Equity Per Share | 123.29 | 104.97 | 75.51 | 38.70 | 33.77 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.16 | 0.18 | 0.24 | 0.24 | 0.27 |
| Revenue Per Share | 152.40 | 157.01 | 118.03 | 89.68 | 52.49 |
| Net Income Per Share | 23.90 | 32.13 | 25.19 | 11.89 | 8.03 |
| Tax Burden | 0.56 | 0.79 | 0.75 | 0.76 | 0.73 |
| Interest Burden | 1.60 | 0.91 | 0.77 | 0.96 | 0.98 |
| Research & Development to Revenue | 0.04 | 0.04 | 0.02 | 0.01 | 0.01 |
| SG&A to Revenue | 0.20 | 0.19 | 0.10 | 0.08 | 0.12 |
| Stock-Based Compensation to Revenue | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Income Quality | 1.42 | 0.20 | 1.14 | 1.09 | 1.21 |
Currency in TWD
